Park Ha Biological Technology Holds 2025 Annual Meeting

TL;DR

Park Ha Bio Tech held its annual shareholder meeting Oct 3rd, standard procedure.

AI Summary

Park Ha Biological Technology Co., Ltd. held its 2025 Annual General Meeting on October 3, 2025, in Wuxi, Jiangsu Province, China. The meeting addressed matters submitted to security holders for a vote, as is customary for a foreign private issuer filing a Form 6-K.

Why It Matters

This filing indicates a routine corporate governance event for Park Ha Biological Technology, confirming the company is adhering to its reporting obligations as a foreign private issuer.

Risk Assessment

Risk Level: low — The filing reports on a routine annual general meeting, which typically does not introduce new material risks.

Key Players & Entities

• Park Ha Biological Technology Co., Ltd. (company) — Registrant
• October 3, 2025 (date) — Date of Annual General Meeting
• Wuxi, Jiangsu Province, People's Republic of China (location) — Location of principal executive office and meeting

FAQ

Key Financial Figures

• $250,000.00 — the Company’s share capital by US$250,000.00 such that the Company will be authorize
• $300,000 — e Company will be authorized to issue US$300,000 divided into 15,000,000,000 ordinary sh
• $0.00002 — ,000,000 ordinary shares of par value US$0.00002 each; and (b) such shares will be and i

Filing Documents

• ea0260614-6k_parkha.htm (6-K) — 23KB
• ea026061401ex3-1_parkha.htm (EX-3.1) — 204KB
• 0001213900-25-097216.txt ( ) — 228KB

From the Filing

OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2025 Commission File No. 001-42453 PARK HA BIOLOGICAL TECHNOLOGY CO., LTD. (Translation of registrant’s name into English) 901, Building C Phase 2, Wuxi International Life Science Innovation Campus 196 Jinghui East Road Xinwu District, Wuxi, Jiangsu Province People’s Republic of China 214000 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F Form 40-F Submission of Matters to a Vote of Security Holders. On October 3, 2025, Park Ha Biological Technology Co., Ltd. (the “Company”) held the 2025 Annual General Meeting (the “Meeting”) at 10 a.m., local time, at 901, Building C Phase 2, Wuxi International Life Science Innovation Campus, 196 Jinghui East Road, Xinwu District, Wuxi, Jiangsu Province, People’s Republic of China 214000. Each ordinary share is entitled to one vote. Holders of a total of 21,872,753 ordinary shares, out of a total of 33,874,403 ordinary shares issued and outstanding and entitled to vote at the Meeting have voted. Therefore, a quorum of two shareholders entitled to vote and present at the meeting in person or by proxy (or, in the case of a corporate shareholder, by its duly authorized representative) at the Meeting as of the record date of September 8, 2025 was reached. The final voting results for each matter submitted to a vote of shareholders at the Meeting are as follows: 1. RE-DESIGNATION AND RE-CLASSIFICATION OF SHARES. It was approved (a) to increase the Company’s share capital by US$250,000.00 such that the Company will be authorized to issue US$300,000 divided into 15,000,000,000 ordinary shares of par value US$0.00002 each; and (b) such shares will be and is hereby re-classified and re-designated as 15,000,000,000 shares in aggregate divided into 12,000,000,000 Class A ordinary shares with a par value of US$0.00002 each with 1 vote per share (the “Class A Ordinary Shares”), and 3,000,000,000 Class B ordinary shares with a par value of US$0.00002 each with 20 votes per share (the “Class B Ordinary Shares”), the current issued and outstanding 33,874,403 ordinary shares of par value of US$0.00002 each be and are re-classified and re-designated as Class A Ordinary Shares (the “Dual-Class Share Capital”), and the 19,050,000 Class A Ordinary Shares held by Xiaoqiu Zhang be surrendered for nil consideration, and the issuance of 19,050,000 Class B Ordinary Shares to Xiaoqiu Zhang, such that, the Company shall become authorized to issue US$300,000 divided into 15,000,000,000 ordinary shares of par value US$0.00002 each divided into (i) 12,000,000,000 Class A ordinary shares with a par value of US$0.00002 each with 1 vote per share and (ii) 3,000,000,000 Class B ordinary shares with a par value of US$0.00002 each with 20 votes per share. For Against Abstain 21,655,675 213,990 3,088 2. AMENDMENT AND RESTATEMENT OF THE COMPANY’S CURRENT AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION. It was approved to amend and restate the Company’s current amended and restated memorandum and articles of association to reflect the Dual-Class Share Capital Structure by adoption of the New Amended and Restated Memorandum and Articles of Association in the form attached as Exhibit 3.1 to reflect the change in the authorized share capital and to set out the rights and privileges of Class A Ordinary Shares and Class B Ordinary Shares and to streamline the shareholders’ meeting and requirements. For Against Abstain 21,653,388 216,112 3,253 The foregoing description of the amendments is qualified in its entirety by reference to the full text of the New Amended and Restated Memorandum and Articles of Association, a copy of which is attached as Exhibit 3.1 hereto and is incorporated by reference herein. 1 3. THE SHARE CONSOLIDATION. It was approved that a share consolidation (the “Share Consolidation”) of the Company’s authorized issued and unissued ordinary shares at a ratio from one (1)-for-five (5) to one (1)-for-thirty (30), with the exact ratio to be set at a whole number within this range to be determined by the Company’s Board in its discretion to be effective on a date as may be determined by the Board and announced by the Company no later than the first anniversary of the Record Date. Such post-consolidated Class A Ordinary Shares having the same rights and being subject to the same restrictions as the pre-consolidated Class A Ordinary Shares and such post-consolidated Class B Ordinary Shares having the same rights and being subject to the same restrictions a

View Full Filing

View this 6-K filing on SEC EDGAR